Is PEPG or CCCC more profitable?

PepGen has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. C4 Therapeutics' return on equity of -50.68% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% C4 Therapeutics -297.76% -50.68% -33.22%

Which has better valuation & earnings, PEPG or RZLT?

Rezolute is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Rezolute N/A N/A -$74.41M -$0.82 N/A

Is PEPG or RZLT more profitable?

Rezolute's return on equity of -58.82% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Rezolute N/A -58.82% -54.48%

Which has higher earnings & valuation, EVMN or PEPG?

Evommune has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $13M 33.83 -$68.87M -$9.50 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is EVMN or PEPG more profitable?

Evommune's return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A PepGen N/A -59.89% -49.62%

Does the media favor EVMN or PEPG?

In the previous week, Evommune had 6 more articles in the media than PepGen. MarketBeat recorded 9 mentions for Evommune and 3 mentions for PepGen. Evommune's average media sentiment score of 1.40 beat PepGen's score of 0.93 indicating that Evommune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, EOLS or PEPG?

Evolus has higher revenue and earnings than PepGen. Evolus is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evolus $297.18M 1.43 -$51.64M -$0.67 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is EOLS or PEPG more profitable?

PepGen has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets Evolus -14.39% N/A -19.03% PepGen N/A -59.89% -49.62%

Does the media refer more to EOLS or PEPG?

In the previous week, Evolus had 1 more articles in the media than PepGen. MarketBeat recorded 4 mentions for Evolus and 3 mentions for PepGen. PepGen's average media sentiment score of 0.93 beat Evolus' score of 0.38 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, PEPG or BNTC?

Benitec Biopharma is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A Benitec Biopharma N/A N/A -$37.92M -$1.14 N/A

Is PEPG or BNTC more profitable?

Benitec Biopharma's return on equity of -34.82% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% Benitec Biopharma N/A -34.82% -34.11%

PepGen (PEPG) Competitors

$2.54 +0.10 (+4.06%)

As of 12:36 PM Eastern

Compare

PEPG vs. CCCC, RZLT, EVMN, EOLS, and BNTC

Should you buy PepGen stock or one of its competitors? MarketBeat compares PepGen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PepGen include C4 Therapeutics (CCCC), Rezolute (RZLT), Evommune (EVMN), Evolus (EOLS), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry.

How does PepGen compare to C4 Therapeutics?

PepGen (NASDAQ:PEPG) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

PepGen has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. C4 Therapeutics' return on equity of -50.68% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

PepGen has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
C4 Therapeutics	$35.95M	11.86	-$104.99M	-$1.19	N/A

PepGen presently has a consensus target price of $11.50, indicating a potential upside of 353.65%. C4 Therapeutics has a consensus target price of $7.75, indicating a potential upside of 101.04%. Given PepGen's stronger consensus rating and higher possible upside, equities research analysts plainly believe PepGen is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

58.0% of PepGen shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 1.3% of PepGen shares are owned by insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, PepGen had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 3 mentions for PepGen and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.43 beat PepGen's score of 0.93 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PepGen	Positive
C4 Therapeutics	Positive

PepGen has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.9, indicating that its share price is 190% more volatile than the broader market.

Summary

C4 Therapeutics beats PepGen on 8 of the 15 factors compared between the two stocks.

How does PepGen compare to Rezolute?

PepGen (NASDAQ:PEPG) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

PepGen currently has a consensus price target of $11.50, indicating a potential upside of 353.65%. Rezolute has a consensus price target of $9.38, indicating a potential upside of 96.75%. Given PepGen's stronger consensus rating and higher possible upside, equities research analysts clearly believe PepGen is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Rezolute is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

Rezolute's return on equity of -58.82% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Rezolute	N/A	-58.82%	-54.48%

PepGen has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

58.0% of PepGen shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 14.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, PepGen had 2 more articles in the media than Rezolute. MarketBeat recorded 3 mentions for PepGen and 1 mentions for Rezolute. Rezolute's average media sentiment score of 1.89 beat PepGen's score of 0.93 indicating that Rezolute is being referred to more favorably in the news media.

Company	Overall Sentiment
PepGen	Positive
Rezolute	Very Positive

Summary

Rezolute beats PepGen on 7 of the 13 factors compared between the two stocks.

How does PepGen compare to Evommune?

Evommune (NYSE:EVMN) and PepGen (NASDAQ:PEPG) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

58.0% of PepGen shares are held by institutional investors. 1.3% of PepGen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Evommune has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	33.83	-$68.87M	-$9.50	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

Evommune currently has a consensus target price of $45.63, indicating a potential upside of 273.67%. PepGen has a consensus target price of $11.50, indicating a potential upside of 353.65%. Given PepGen's higher possible upside, analysts plainly believe PepGen is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Evommune's return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
PepGen	N/A	-59.89%	-49.62%

In the previous week, Evommune had 6 more articles in the media than PepGen. MarketBeat recorded 9 mentions for Evommune and 3 mentions for PepGen. Evommune's average media sentiment score of 1.40 beat PepGen's score of 0.93 indicating that Evommune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Evommune beats PepGen on 10 of the 14 factors compared between the two stocks.

How does PepGen compare to Evolus?

Evolus (NASDAQ:EOLS) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Evolus currently has a consensus target price of $16.00, suggesting a potential upside of 147.33%. PepGen has a consensus target price of $11.50, suggesting a potential upside of 353.65%. Given PepGen's stronger consensus rating and higher possible upside, analysts plainly believe PepGen is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

90.7% of Evolus shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 5.0% of Evolus shares are owned by insiders. Comparatively, 1.3% of PepGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Evolus has higher revenue and earnings than PepGen. Evolus is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.43	-$51.64M	-$0.67	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

Evolus has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, PepGen has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

In the previous week, Evolus had 1 more articles in the media than PepGen. MarketBeat recorded 4 mentions for Evolus and 3 mentions for PepGen. PepGen's average media sentiment score of 0.93 beat Evolus' score of 0.38 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PepGen has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
PepGen	N/A	-59.89%	-49.62%

Summary

Evolus beats PepGen on 8 of the 15 factors compared between the two stocks.

How does PepGen compare to Benitec Biopharma?

PepGen (NASDAQ:PEPG) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

PepGen presently has a consensus target price of $11.50, suggesting a potential upside of 353.65%. Benitec Biopharma has a consensus target price of $27.00, suggesting a potential upside of 102.93%. Given PepGen's stronger consensus rating and higher possible upside, equities analysts clearly believe PepGen is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, PepGen had 2 more articles in the media than Benitec Biopharma. MarketBeat recorded 3 mentions for PepGen and 1 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.87 beat PepGen's score of 0.93 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
PepGen	Positive
Benitec Biopharma	Very Positive

PepGen has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

Benitec Biopharma's return on equity of -34.82% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Benitec Biopharma	N/A	-34.82%	-34.11%

58.0% of PepGen shares are owned by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Benitec Biopharma is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

Summary

PepGen and Benitec Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

Get PepGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEPG vs. The Competition

Export

Metric	PepGen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$174.65M	$3.64B	$6.74B	$12.51B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.44	21.01	26.90	24.39
Price / Sales	N/A	314.09	587.69	117.46
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.18	8.50	10.92	6.33
Net Income	-$89.65M	$23.83M	$3.58B	$330.66M
7 Day Performance	23.66%	-3.45%	-2.25%	-0.84%
1 Month Performance	72.45%	6.33%	3.08%	-0.26%
1 Year Performance	96.51%	48.44%	26.23%	19.99%

PepGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEPG PepGen	2.578 of 5 stars	$2.54 +4.1%	$11.50 +352.9%	+93.7%	$175.62M	N/A	N/A	30	News Coverage
CCCC C4 Therapeutics	1.8063 of 5 stars	$4.14 -3.7%	$7.75 +87.2%	+75.8%	$475.44M	$35.95M	N/A	150
RZLT Rezolute	3.2601 of 5 stars	$4.93 +0.4%	$9.38 +90.2%	-9.9%	$472.80M	N/A	N/A	40
EVMN Evommune	3.7941 of 5 stars	$12.31 -5.0%	$45.63 +270.6%	N/A	$466.80M	$13M	N/A	45
EOLS Evolus	2.2385 of 5 stars	$6.99 +1.3%	$16.00 +128.9%	-31.2%	$454.40M	$297.18M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PEPG) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PepGen (PEPG) Competitors

PEPG vs. CCCC, RZLT, EVMN, EOLS, and BNTC

How does PepGen compare to C4 Therapeutics?

Summary

How does PepGen compare to Rezolute?

Summary

How does PepGen compare to Evommune?

Summary

How does PepGen compare to Evolus?

Summary

How does PepGen compare to Benitec Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PepGen (PEPG) Competitors

PEPG vs. CCCC, RZLT, EVMN, EOLS, and BNTC

How does PepGen compare to C4 Therapeutics?

Is PEPG or CCCC more profitable?

Which has preferable earnings and valuation, PEPG or CCCC?

Do analysts rate PEPG or CCCC?

Do institutionals and insiders believe in PEPG or CCCC?

Does the media prefer PEPG or CCCC?

Which has more volatility and risk, PEPG or CCCC?

Summary

How does PepGen compare to Rezolute?

Do analysts recommend PEPG or RZLT?

Which has better valuation & earnings, PEPG or RZLT?

Is PEPG or RZLT more profitable?

Which has more volatility & risk, PEPG or RZLT?

Do institutionals & insiders have more ownership in PEPG or RZLT?

Does the media favor PEPG or RZLT?

Summary

How does PepGen compare to Evommune?

Do insiders and institutionals believe in EVMN or PEPG?

Which has higher earnings & valuation, EVMN or PEPG?

Do analysts prefer EVMN or PEPG?

Is EVMN or PEPG more profitable?

Does the media favor EVMN or PEPG?

Summary

How does PepGen compare to Evolus?

Do analysts prefer EOLS or PEPG?

Do institutionals and insiders hold more shares of EOLS or PEPG?

Which has preferable valuation & earnings, EOLS or PEPG?

Which has more risk & volatility, EOLS or PEPG?

Does the media refer more to EOLS or PEPG?

Is EOLS or PEPG more profitable?

Summary

How does PepGen compare to Benitec Biopharma?

Do analysts recommend PEPG or BNTC?

Does the media prefer PEPG or BNTC?

Which has more risk and volatility, PEPG or BNTC?

Is PEPG or BNTC more profitable?

Do insiders and institutionals hold more shares of PEPG or BNTC?

Which has stronger valuation and earnings, PEPG or BNTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools